Medexus Pharmaceuticals announced that Health Canada recently accepted for review Medexus's new drug submission, or NDS, for terbinafine hydrochloride nail lacquer to treat fungal nail infections. Medexus's NDS for topical terbinafine seeks Health Canada approval for a distinctive once-a week treatment regimen. If and when approved, the product will enter the Canadian topical fungicides market that is estimated to be CAD 88 million on an annual basis.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.62 CAD | +1.25% | +1.25% | -34.41% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.41% | 28.76M | |
+38.42% | 705B | |
+32.60% | 583B | |
-3.02% | 364B | |
+20.87% | 332B | |
+5.89% | 291B | |
+16.21% | 238B | |
-3.52% | 210B | |
+10.50% | 209B | |
+9.40% | 169B |
- Stock Market
- Equities
- MDP Stock
- News Medexus Pharmaceuticals Inc.
- Medexus Pharmaceuticals Announces Health Canada Accepts for Review Medexus's New Drug Submission, or NDS, for Terbinafine Hydrochloride Nail Lacquer to Treat fungal N Infections